The Future of BCMA-Targeting in Myeloma
By DocWire News Editors - Last Updated: April 27, 2023Noopur Raje, MD, Director of the Multiple Myeloma Program at Massachusetts General Hospital, looks into the future of BCMA-targeting CAR T-cell therapies such as bb21217 and how this class of agents will fit in the myeloma treatment landscape.
Advertisement
Advertisement
Related Posts
Parkinson's disease and melanoma are believed to be linked due to DNA double-strand break repair thus cell proliferation.
Dr. Eric Dr. Bergson about the importance of head and neck cancer awareness, how to integrate screening into routine care.
AI analysis provides an opportunity for timely intervention to improve the ability to swallow as well as quality of life.
Euphorbis tirucalli leaf extract has the potential ability to inhibit EBV-positive cell proliferation.
A study has uncovered a novel method to enhance immunotherapy for melanoma by targeting a protein known as MARCO.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.